9 results
6-K
EX-99.1
ALVO
Alvotech
21 May 24
Current report (foreign)
8:41am
.
Prolia® and Xgeva® are indicated for the treatment of various diseases including osteoporosis in postmenopausal women and prevention of skeletal-related … presentations. Prolia® is indicated for the treatment of osteoporosis in postmenopausal women and for bone loss in adult men and women at increased risk
6-K
EX-99.3
ALVO
Alvotech
20 Mar 24
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
4:30pm
manufacturing operations scale.
Alvotech Non-Financial Disclosures 2023
Key social performance indicators
Social
Unit
Ratio of pay of men to women …
Growth of total headcount
Women in management (ratio to total headcount)
Women in the company excluding management (ratio to total headcount)
Ratio
6-K
EX-99.1
ALVO
Alvotech
29 Jan 24
Current report (foreign)
7:00am
Scientific Officer.
Prolia (denosumab) is indicated for the treatment of osteoporosis in postmenopausal women and for bone loss in adult men and women
424B3
ALVO
Alvotech
1 Dec 22
Prospectus supplement
5:27pm
and was recognized earlier this year by the Association of Icelandic Women in Business (FKA) for her work on motivating and supporting women in business
424B3
reenkr
1 Dec 22
Prospectus supplement
5:25pm
6-K
EX-99.2
zztffc
1 Dec 22
Alvotech submits its application for admission of the company’s shares to trading on Nasdaq Iceland Main Market
5:20pm
6-K
EX-99.1
0lr9htl
25 Aug 22
Current report (foreign)
6:02am
6-K
EX-99.1
jyqjb4vy72cmw
20 Jul 22
Prolia® and Xgeva® (denosumab) are indicated for the treatment of bone disease, with combined sales of nearly US$5.3 billion in 2021
5:12pm
- Prev
- 1
- Next